A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma

NCT03730142 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: WXFL10030390

Sponsor

Shanghai Jiatan Pharmatech Co., Ltd